Certara, Inc. (NASDAQ:CERT) Given Average Recommendation of “Hold” by Brokerages

Certara, Inc. (NASDAQ:CERT) has been assigned a consensus recommendation of “Hold” from the fourteen brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $11.10.

Several research firms have issued reports on CERT. Leerink Partners restated an “outperform” rating and set a $10.00 price objective on shares of Certara in a report on Thursday, February 26th. Stephens dropped their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, December 12th. KeyCorp cut their price target on shares of Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, January 8th. Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. Finally, Morgan Stanley decreased their price objective on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th.

Certara Stock Performance

CERT opened at $6.65 on Monday. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The firm has a market cap of $1.06 billion, a PE ratio of -665.00 and a beta of 1.50. The business has a fifty day simple moving average of $7.98 and a 200-day simple moving average of $9.62. Certara has a fifty-two week low of $6.04 and a fifty-two week high of $15.38.

Certara (NASDAQ:CERT) last announced its earnings results on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The company had revenue of $103.65 million for the quarter, compared to analysts’ expectations of $103.23 million. During the same period in the prior year, the company earned $0.15 earnings per share. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts predict that Certara will post 0.28 EPS for the current fiscal year.

Institutional Trading of Certara

Hedge funds and other institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. raised its position in Certara by 2,733.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after buying an additional 2,870 shares during the period. First Horizon Corp acquired a new stake in Certara during the 3rd quarter worth about $30,000. Versant Capital Management Inc boosted its position in Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after acquiring an additional 1,153 shares during the period. Osaic Holdings Inc. grew its stake in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new position in shares of Certara in the 2nd quarter valued at about $59,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.